This page describes resources for healthcare professionals to support their patients with CSU.

Patient resources are recommended as a tool for the consistent monitoring of symptoms and routine management of CSU, as1–3: 

  • the severity of symptoms can change day to day4
  • no established biomarkers currently exist for CSU5,6
  • key symptoms (such as itch and pain) can only be assessed subjectively

As part of our mission to be as environmentally friendly as possible, we provide our resources in electronic form. These materials should not be printed by healthcare professionals.


Click on the links below to view the patient reported outcomes resources, and if you have any further requests, please contact a Novartis representative.



Symptom control

Four questions


Retrospective (4 weeks)

Use at first consultation and every follow-up consultation


Disease severity

Two questions

Symptoms scored daily

Prospective (1 week)

Use at every follow-up consultation


Quality of life

10 questions

Not specific to CSU

Retrospective (1 week)

Use at first consultation and every 6 months thereafter

View  the Understanding Urticaria resource for healthcare professionals to use in supporting their patients with CSU.

Sharing best practice in CSU


*Recommended for evaluating CSU control and monitoring CSU status in routine clinical practice by the EAACI/GA2LEN/EDF/WAO international urticaria guidelines.1

Recommended for monitoring quality of life of patients with urticaria by EAACI/ GA2LEN/EDF/WAO, NICE and the BSACI.1,10

BAD, British Association of Dermatologists; BSACI, British Society for Allergy & Clinical Immunology; CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; EAACI, European Academy of Allergy and Clinical Immunology; EDF, European Dermatology Forum; GA2LEN, Global Allergy and Asthma European Network; UAS7, urticaria activity score at seven days; UCT, urticaria control test; WAO, World Allergy Organization.


  1. Zuberbier T et al. Allergy 2018;73(7):1393–1414.
  2. Maurer M, et al. Allergy 2011;66:317–330
  3. Moestrup K et al. Int J Dermatol 2017;56(12):1342–1348.
  4. Flood EM et al. Patient 2013;6(3):225–231.
  5. Kolkhir P et al. Clin Exp Allergy 2017;47(1):19–36.
  6. Marzano AV et al. J Eur Acad Dermatol Venereol 2019;33(5):918–924.
  7. Weller K et al. J Allergy Clin Immunol 2014;133(5):1365-1372, 1372 e1361–1366.
  8. Mlynek A et al. Allergy 2008;63(6):777–780.
  9. Finlay AY et al. Clin Exp Dermatol 1994;19(3):210–216.
  10. Powell RJ et al. Clin Exp Allergy 2015;45(3):547–565.
Rate this content: 
No votes yet
XSU20-C021 July 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]